Company profile: 4P-Pharma
1.1 - Company Overview
Company description
- Provider of clinical-stage regenerating active drugs and therapies for serious diseases, including 4P004, a GLP-1 analog for osteoarthritis; 4P022, an AI platform-based treatment for systemic sclerosis; 4P025 for primary sclerosing cholangitis; 4P021, a CXCR4 antagonist for acute respiratory distress syndrome and pulmonary complications; and 4P020, a beta-3 adrenergic receptor agonist for Stargardt disease and dry age-related macular degeneration.
Products and services
- 4P004: A regenerative-oriented GLP-1 analog drug candidate engineered for osteoarthritis, exhibiting anti-inflammatory, anti-catabolic, and anabolic properties to counter joint degradation and foster tissue rebuilding
- 4P020: A receptor-specific beta-3 adrenergic receptor agonist developed to treat Stargardt disease and dry age-related macular degeneration, pharmacologically activating beta-3 pathways for these defined ophthalmic indications
- 4P021: An antagonist-class CXCR4 agent produced for treating acute respiratory distress syndrome and pulmonary complications, using receptor antagonism to intervene in respiratory impairment
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to 4P-Pharma
Conformal Medical
HQ: United States
Website
- Description: Provider of transcatheter left atrial appendage occlusion solutions to prevent stroke in patients with nonvalvular atrial fibrillation, including the Conformal Left Atrial Appendage System (CLAAS) implant and the CONFORM clinical trial evaluating CLAAS versus other commercially available LAAO devices.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Conformal Medical company profile →
Acticor Biotech
HQ: France
Website
- Description: Provider of biopharmaceutical development of glenzocimab, a humanized monoclonal antibody fragment targeting platelet GPVI with antithrombotic properties without increasing bleeding risk, for the acute phase of ischemic stroke. Runs clinical trials: ACTISAVE, ACTIMIS, and GREEN in stroke, LIBERATE in myocardial infarction, and GARDEN in SARS-CoV-2-related ARDS.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Acticor Biotech company profile →
Prexton Therapeutics
HQ: Switzerland
Website
- Description: Provider of biopharmaceutical drug development focused on innovative drugs to improve quality of life. Swiss-based, founded in 2012 by Francois Conquet and MS Ventures under the Merck Serono Entrepreneur Partnership Program, applying a new scientific approach.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Prexton Therapeutics company profile →
Interactive Motion Technologies
HQ: United States
Website
- Description: Provider of robotic solutions for patients with neurological conditions, offering evidence-based InMotion Robots developed from medical engineering research at MIT’s Newman Laboratory for Biomechanics and Human Rehabilitation, tested by leading medical centers worldwide for 10 years in over 40 studies.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Interactive Motion Technologies company profile →
Vico Therapeutics
HQ: The Netherlands
Website
- Description: Provider of RNA-modulating therapies for rare neurological/CNS disorders, focused on SCA, HD and RTT. Offers VO659, an antisense oligonucleotide targeting CAG repeat expansions in polyglutamine diseases (Spinocerebellar Ataxia types 1/3 and Huntington’s) to reduce mutant protein levels and improve motor function, and VICOMER, a platform designing RNA therapeutics via translation, splicing, editing, degradation and activation.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Vico Therapeutics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for 4P-Pharma
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to 4P-Pharma
2.2 - Growth funds investing in similar companies to 4P-Pharma
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for 4P-Pharma
4.2 - Public trading comparable groups for 4P-Pharma
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →